ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
27.90
-0.52 (-1.83%)
At close: May 15, 2026, 4:00 PM EDT
27.87
-0.03 (-0.11%)
After-hours: May 15, 2026, 4:10 PM EDT
ArriVent BioPharma Employees
ArriVent BioPharma had 77 employees as of December 31, 2025. The number of employees increased by 25 or 48.08% compared to the previous year.
Employees
77
Change (1Y)
25
Growth (1Y)
48.08%
Revenue / Employee
n/a
Profits / Employee
-$1,886,247
Market Cap
1.30B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 77 | 25 | 48.08% |
| Dec 31, 2024 | 52 | 12 | 30.00% |
| Dec 31, 2023 | 40 | - | - |
| Sep 30, 2023 | 42 | - | - |
| Jun 30, 2023 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| AbCellera Biologics | 562 |
| Wave Life Sciences | 317 |
| Biohaven | 274 |
| MapLight Therapeutics | 133 |
| MoonLake Immunotherapeutics | 130 |
| Bicara Therapeutics | 103 |
| GH Research | 73 |
AVBP News
- 3 days ago - ArriVent Biopharma price target lowered to $43 from $45 at Citi - TheFly
- 5 days ago - ArriVent Biopharma reports Q1 EPS (96c), consensus (89c) - TheFly
- 5 days ago - ArriVent BioPharma Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 9 days ago - ArriVent Biopharma announces FDA clearance of ARR-002 NDA - TheFly
- 9 days ago - ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers - GlobeNewsWire
- 22 days ago - Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’ - TheFly
- 7 weeks ago - ArriVent Biopharma price target raised to $45 from $37 at B. Riley - TheFly
- 2 months ago - ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - GlobeNewsWire